Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: BioNTech SE

Market Cap 19.93B 22.81B 18.43B 17.21B 32.3B 2,155B 32.54B 219B 85.23B 1,060B 85.63B 83.77B 3,681B P/E 2026 *
-17.9x
P/E 2027 * -17.6x
Enterprise Value 9.08B 10.39B 8.4B 7.84B 14.71B 982B 14.82B 99.77B 38.82B 483B 39B 38.16B 1,677B EV / Sales 2026 *
4.19x
EV / Sales 2027 * 4.77x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-20.52%+2.41% - - 22.81B
+1.66%+7.14%+73.78%+122.96% 56.65B
+4.00%+7.51%+63.67%+68.77% 47.49B
+1.03%+5.11%-4.76%+403.03% 21.37B
+1.30%+3.73%+27.10%-17.51% 16.12B
+3.16%+9.42%+25.83%-34.97% 15.56B
-0.31%-2.05%+17.66%+156.95% 12.91B
+3.30%+15.02%+133.24%+273.89% 12.86B
+1.43%-6.44%+21.49% - 11.67B
+1.67%+2.58%+81.67%+116.31% 11.82B
Average +1.95%+2.97%+48.85%+136.18% 22.94B
Weighted average by Cap. +2.20%+3.90%+53.76%+128.05%

Financials

2026 *2027 *
Net sales 2.17B 2.48B 2B 1.87B 3.51B 234B 3.54B 23.81B 9.26B 115B 9.31B 9.1B 400B 2.23B 2.55B 2.06B 1.93B 3.62B 241B 3.64B 24.52B 9.54B 119B 9.58B 9.38B 412B
Net income -1.05B -1.2B -972M -907M -1.7B -114B -1.72B -11.55B -4.49B -55.88B -4.52B -4.42B -194B -1.17B -1.33B -1.08B -1.01B -1.89B -126B -1.9B -12.81B -4.98B -61.97B -5.01B -4.9B -215B
Net Debt -10.85B -12.42B -10.04B -9.37B -17.59B -1,174B -17.72B -119B -46.41B -577B -46.63B -45.62B -2,005B -9.28B -10.62B -8.58B -8.01B -15.04B -1,004B -15.15B -102B -39.69B -493B -39.88B -39.01B -1,714B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!